Beta-lactamase phenotype could be result of expression of more than one gene, and there is more than one mechanism that grants staphylococci beta-lactam resistance other than the expression of blaZ ...

With the emergence and rapid spreading of NDM-1 and existence of clinically relevant VIM-1 and IMP-1, discovery of pan inhibitors targeting metallo-beta-lactamases (MBLs) became critical in our battle ...

Plasmid-mediated AmpC production. Of the 134 third generation cephalosporin resistant strains, 63(47%) were positive for plasmid-mediated AmpC beta lactamases. 75% of Proteus were stable AmpC ...

The global rise of metallo-β-lactamases (MBLs) is problematic due to their ability to inactivate most β-lactam antibiotics. MBL inhibitors that could be coadministered with and restore the efficacy of ...

The drug – a combination of beta-lactam antibiotic aztreonam with beta-lactamase inhibitor avibactam – is the first monobactam/β-lactamase inhibitor combination to be cleared in the US for ...

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens ...

† VIMs are made up of 266 amino acid residues with the exception of VIM-7 (265 residues) and VIM-18 (262 residues). VIM-21, -22 and -27 have been assigned in the Lahey Clinic [201], but there ...

U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- ...

Iterum Therapeutics Announces Partnership for Commercialization Services U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at ...

Antibiotic and other antimicrobial resistance could hamstring important medications. One Canadian initiative brings together ...